导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.60% | 2249/4773 |
| 近一周 | -2.03% | 3284/5465 |
| 近一月 | -5.36% | 3733/5421 |
| 近一季 | -10.37% | 3746/5231 |
| 近半年 | -4.61% | 2881/4920 |
| 近一年 | 4.54% | 1842/4394 |
| 近两年 | 60.85% | 1215/2954 |
| 近三年 | 32.16% | 1013/2253 |
| 成立以来 | 111.28% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.35% 1768/4961 |
16.55% 1555/5312 |
- - |
- - |
| 2025 | 30.49% 1313/4813 |
3.19% 1159/3635 |
0.39% 2670/4076 |
27.16% 1308/4524 |
-0.94% 2734/4813 |
| 2024 | 7.29% 1674/3463 |
-3.62% 1531/2808 |
-1.08% 921/3014 |
14.26% 2020/3129 |
-1.51% 1733/3463 |
| 2023 | -16.35% 1679/2656 |
5.41% 787/2280 |
-6.23% 1604/2385 |
-10.04% 1943/2515 |
-5.93% 1562/2655 |
| 2022 | -24.14% 1192/2207 |
-17.35% 1198/1919 |
8.71% 333/2016 |
-15.46% 1299/2113 |
-0.12% 1566/2208 |
| 2021 | 10.17% 440/1822 |
-5.33% 916/1255 |
12.79% 310/1330 |
-2.88% 600/1466 |
6.24% 223/1822 |
| 2020 | 45.30% 219/1250 |
-1.60% 225/1028 |
22.45% 206/1067 |
9.37% 653/1164 |
10.25% 607/1184 |
| 2019 | 39.84% 268/1092 |
32.98% 152/754 |
-9.44% 653/804 |
5.66% 139/850 |
9.89% 180/918 |
| 2018 | -34.52% 571/834 |
- - |
- - |
- - |
-16.15% 626/691 |
| 2017 | 15.80% 244/714 |
- - |
- - |
- - |
- - |
| 2016 | -22.81% 461/605 |
- - |
- - |
- - |
- - |
| 2015 | 51.21% 19/575 |
- - |
- - |
- - |
- - |
| 2014 | 8.16% 214/237 |
- - |
- - |
- - |
- - |
| 2013 | 15.20% 26/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 申万菱信中小企业100指数(LOF)A VS. 长安沪深300非周期A(740101) |